Efficacy, safety, and cost-effectiveness analysis of Cerebrolysin in acute ischemic stroke: A rapid health technology assessment
Open Access
- 29 March 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (13) , e37593
Abstract
This study conducts a rapid health technology assessment to systematically evaluate the effectiveness, safety, and cost-effectiveness of Cerebrolysin as an adjunctive therapy for acute ischemic stroke to provide evidence-based medicine for clinical decisions of Cerebrolysin. All systematic reviews/meta-analyses, pharmacoeconomic studies, and health technology assessment reports of Cerebrolysin for the treatment of acute ischemic stroke before August 17, 2023, were retrieved from PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Wanfang, Weipu, Sinomed database and the official website of health technology assessment. According to the inclusion and exclusion criteria, 2 researchers independently carried out screening, data extraction, and quality evaluation and descriptively analyzed the results of the included studies. A total of 14 pieces of literature were incorporated, comprising 8 systematic reviews/meta-analyses and 6 pharmacoeconomic studies. In terms of effectiveness, compared to control groups, the use of Cerebrolysin as a treatment for acute ischemic stroke demonstrates certain advantages, including enhancement in total efficacy rate, neurological function, upper limb motor dysfunction, and facilitation of the recovery of activities of daily living. Especially in patients with moderate to severe acute ischemic stroke, Cerebrolysin has demonstrated the ability to enhance neurological function recovery and ameliorate disabilities. Regarding safety, adverse reactions were mild or comparable to those in the control group. The primary findings of economic studies reveal that advocating for the use of Cerebrolysin offers certain cost-effectiveness advantages. Cerebrolysin contributes to improved clinical efficacy and evaluation indexes while demonstrating favorable safety and economic benefits.Keywords
This publication has 32 references indexed in Scilit:
- What Is Acute Ischemic Stroke?JAMA, 2022
- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic EvaluationsValue in Health, 2022
- Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomesNeurological Sciences, 2021
- Relationship of Barthel Index and its Short Form with the Modified Rankin Scale in acute stroke patientsJournal of Stroke and Cerebrovascular Diseases, 2020
- Prospective, double blinded, comparative assessment of the pharmacological activity of Cerebrolysin and distinct peptide preparations for the treatment of embolic strokeJournal of the Neurological Sciences, 2019
- Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trialsNeurological Sciences, 2017
- Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trialsNeurological Sciences, 2017
- Stroke-related motor outcome measures: Do they quantify the neurophysiological aspects of upper extremity recovery?Journal of Bodywork and Movement Therapies, 2014
- Rapid reviews versus full systematic reviews: An inventory of current methods and practice in health technology assessment: CorrigendumInternational Journal of Technology Assessment in Health Care, 2008
- Clinical interpretation and use of stroke scalesThe Lancet Neurology, 2006